![]() ![]() How were the results observed in patients with metastases to bone and brain? Were there patients with confirmed metastases in two or three different sites? Moreover, the authors did not show data for patients with bone and brain metastasis. ![]() In this type of patients, it could be assumed that they are subjected to other prognostic factors different from the ones being studied. Mainly when it comes to studying potentially causal associations between a certain exposure and an effect or outcome, such as for the analysis of the progression of the disease shown in this study. Therefore, it is of interest to know what prognostic factors influence the survival of this type of patient. The results have selection bias for female patients, patients with "0" ECOG (Eastern Cooperative Oncology Group) performance status, non-smokers, older adults (≥65 y), and patients with liver metastasis. Wang et al show results that suggest the addition of tislelizumab to standard chemotherapy represents an additional treatment option as first-line treatment for patients with advanced squamous non–small-cell lung cancer (sq-NSCLC).1 However, for some variables, the results are limited by their own study design. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.Incidence of treatment-related adverse events occurring in ≥15% of patients Overall summary of treatment emergent adverse eventsĮTable 7. Biomarker interaction analysis for PD-L1 at cutoff of 1% TC per RECIST version 1.1 by independent review committee in ITT analysis setĮTable 6. Progression-free survival by PD-L1 per RECIST version 1.1 by independent review committee in ITT analysis setĮTable 5. Progression-free survival by disease stage per RECIST version 1.1 by independent review committee in ITT analysis setĮTable 4. ![]() Progression-free survival by independent review committee in patients with 2 patients across treatment armsĮTable 1. Progression-free survival by independent review committee in patients with 1-49% tumor cell PD-L1 expressionĮFigure 5. Progression-free survival by independent review committee in patients with ≥50% tumor cell PD-L1 expressionĮFigure 4. Progression-free survival by investigatorĮFigure 3. Criteria and end point defintionsĮFigure 2. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |